東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Development of Circulating Tumor Cel...

Court, Colin MacDonald.

FindBook

Google Book

Amazon

博客來

Development of Circulating Tumor Cell Sequencing as a Biomarker in Gastrointestinal Cancers.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Development of Circulating Tumor Cell Sequencing as a Biomarker in Gastrointestinal Cancers./
作者:	Court, Colin MacDonald.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	245 p.
附註:	Source: Dissertations Abstracts International, Volume: 80-11, Section: B.
Contained By:	Dissertations Abstracts International80-11B.
標題:	Molecular biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13864477
ISBN:	9781392142837

Development of Circulating Tumor Cell Sequencing as a Biomarker in Gastrointestinal Cancers.
Court, Colin MacDonald.

Development of Circulating Tumor Cell Sequencing as a Biomarker in Gastrointestinal Cancers. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 245 p.

Source: Dissertations Abstracts International, Volume: 80-11, Section: B.

Thesis (Ph.D.)--University of California, Los Angeles, 2019.

This item must not be sold to any third party vendors.

For precision oncology to become a reality, clinicians need access to tumor tissue in a real-time, repeatable, and cost-effective manner. Circulating tumor cells (CTCs), cells of tumor origin that circulate in the blood, are one possible solution, with the potential to serve as a "liquid biopsy" for gastrointestinal (GI) tumors.In this thesis, we demonstrate the development and validation of an assay for performing molecular analysis of CTCs as a biomarker for GI cancers. We used a microfluidic platform to develop GI tumor-specific CTC assays for pancreatic and liver cancer through incorporation of tissue-specific markers for CTC capture and identification. We then conducted prospective studies testing the utility of CTC enumeration as a biomarker in pancreatic (n=100) and liver (n=61) cancer. We found that the use of a tissue-specific assay resulted in higher CTC counts than in previous studies, that CTC counts correlated with increasing stage and that CTC enumeration may have diagnostic and prognostic utility as a biomarker in GI cancers.Using a modified assay that allows for the complete isolation of the CTCs identified, we confirmed the tumor origin of the CTCs we identified by comparison of mutational status with the primary tumor using both Sanger and next generation sequencing methods.After confirming their tumor origin, we developed a quality control assay that allowed us to determine how many CTCs we would need to isolate to reliably perform CTC molecular analysis. Using this metric, we modified our CTC sequencing protocol that resulted in reliable sequencing from as few as 3-5 CTCs as opposed to the 10-20 needed using the traditional CTC sequencing protocol. We then used our optimized CTC sequencing protocol in a prospective study to test the feasibility and potential utility of CTC molecular analysis as a biomarker in liver cancer.The research described in this thesis serves two primary goals. The first is as a validated method that allows for the use of CTCs in liquid biopsy-type applications for both HCC and PDAC patients. The second is as a framework for validating CTC assays and definitions to ensure the reliability and reproducibility of CTC sequencing results.

ISBN: 9781392142837Subjects--Topical Terms:

517296
Molecular biology.

Development of Circulating Tumor Cell Sequencing as a Biomarker in Gastrointestinal Cancers.
LDR:03335nmm a2200337 4500 001 2207674
005 20190920102358.5
008 201008s2019 ||||||||||||||||| ||eng d
020 $a 9781392142837
035 $a (MiAaPQ)AAI13864477
035 $a (MiAaPQ)ucla:17659
035 $a AAI13864477
040 $a MiAaPQ $c MiAaPQ
100 1 $a Court, Colin MacDonald. $3 3434661
245 1 0 $a Development of Circulating Tumor Cell Sequencing as a Biomarker in Gastrointestinal Cancers.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 245 p.
500 $a Source: Dissertations Abstracts International, Volume: 80-11, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Graeber, Thomas G.
502 $a Thesis (Ph.D.)--University of California, Los Angeles, 2019.
506 $a This item must not be sold to any third party vendors.
520 $a For precision oncology to become a reality, clinicians need access to tumor tissue in a real-time, repeatable, and cost-effective manner. Circulating tumor cells (CTCs), cells of tumor origin that circulate in the blood, are one possible solution, with the potential to serve as a "liquid biopsy" for gastrointestinal (GI) tumors.In this thesis, we demonstrate the development and validation of an assay for performing molecular analysis of CTCs as a biomarker for GI cancers. We used a microfluidic platform to develop GI tumor-specific CTC assays for pancreatic and liver cancer through incorporation of tissue-specific markers for CTC capture and identification. We then conducted prospective studies testing the utility of CTC enumeration as a biomarker in pancreatic (n=100) and liver (n=61) cancer. We found that the use of a tissue-specific assay resulted in higher CTC counts than in previous studies, that CTC counts correlated with increasing stage and that CTC enumeration may have diagnostic and prognostic utility as a biomarker in GI cancers.Using a modified assay that allows for the complete isolation of the CTCs identified, we confirmed the tumor origin of the CTCs we identified by comparison of mutational status with the primary tumor using both Sanger and next generation sequencing methods.After confirming their tumor origin, we developed a quality control assay that allowed us to determine how many CTCs we would need to isolate to reliably perform CTC molecular analysis. Using this metric, we modified our CTC sequencing protocol that resulted in reliable sequencing from as few as 3-5 CTCs as opposed to the 10-20 needed using the traditional CTC sequencing protocol. We then used our optimized CTC sequencing protocol in a prospective study to test the feasibility and potential utility of CTC molecular analysis as a biomarker in liver cancer.The research described in this thesis serves two primary goals. The first is as a validated method that allows for the use of CTCs in liquid biopsy-type applications for both HCC and PDAC patients. The second is as a framework for validating CTC assays and definitions to ensure the reliability and reproducibility of CTC sequencing results.
590 $a School code: 0031.
650 4 $a Molecular biology. $3 517296
650 4 $a Medicine. $3 641104
650 4 $a Bioinformatics. $3 553671
690 $a 0307
690 $a 0564
690 $a 0715
710 2 $a University of California, Los Angeles. $b Molecular, Cellular, and Integrated Physiology. $3 3434662
773 0 $t Dissertations Abstracts International $g 80-11B.
790 $a 0031
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13864477